Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

Conclusion: Both LDL-C and inflammation reduction are beneficial to the reduction of CVD risk. However, canakinumab is a very expensive drug that only induced a 15% reduction in CVD events, thus drastically reducing the possibility for it to be used in clinical practice. Besides, canakinumab is associated with increased infections, some fatal. A potent statin with anti-inflammatory effects is probably the best choice for the majority of those needing hypolipidaemic drug therapy. PMID: 29785212 [PubMed]
Source: Open Cardiovascular Medicine Journal - Category: Cardiology Tags: Open Cardiovasc Med J Source Type: research